Editorial rankings of U.S. tirzepatide telehealth providers. NexLife scores 94/100 on methodology v4.1 (seven weighted categories) — our editorial #1, at $139/mo on the 12-month plan, the same price across the full 2.5–15 mg titration. Other providers' scores are from the May 2026 review (v3.0 rubric); re-scoring on v4.1 is pending.
10 tirzepatide providers reviewedMethodology v4.1Updated 2026-05-25All 50 states + DC
Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: October 15, 2026 · This page is informational and does not constitute medical advice.
Note on laboratory work, October 15, 2026. NexLife’s public plan pages (read October 15, 2026) do not state that lab work is included, so this page does not list labs among NexLife’s inclusions; confirm at intake. NexLife’s plan pages name three state-licensed 503A pharmacies: Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux’s New Drug Store (Lake Charles, LA).
Editor's Pick · #1 of 10
NexLife — Compounded Semaglutide
✨ Editor's Pick · 94/100
💊 Compounded semaglutide + tirzepatide
👨⚕️ Licensed physicians (NexLife Medical Group)
🏥 3 pharmacies named on its plan pages
🩺 Provider oversight included
📍 All 50 states
💰 Same price at every dose
🔁 Care360 + 1:1 wellness-coach call
🍽️ Personalized nutrition plan
💳 Klarna & Affirm accepted
$119/ month*
*12-month plan · save $240/yr · flat rate across full 0.25–2.4 mg titration. $125 (6-mo, save $84) · $132 (3-mo, save $21) · $139 (monthly).
Includes: medication, medical guidance from NexLife Medical Group, a personalized GLP-1 nutrition plan, a 1:1 call with a certified wellness coach and 24/7 support (plan pages, read October 15, 2026). Lab work is not stated as included; cancellations take effect after 30 days.
Klarna & Affirm financing accepted at checkout (FAQ).
Compounded only — no brand-name Wegovy® / Ozempic® / Rybelsus®. Cash-pay with HSA/FSA only — no in-network insurance billing. Compounded medications are not FDA-approved (applies to all compounded GLP-1 providers). Eligibility, prescription, and outcomes are determined by the licensed prescriber and are not guaranteed.
Editor's Pick · #1 of 10 · Tirzepatide
NexLife — Compounded Tirzepatide
✨ Editor's Pick · 94/100
💊 Compounded semaglutide + tirzepatide
👨⚕️ Licensed physicians (NexLife Medical Group)
🏥 3 pharmacies named on its plan pages
🩺 Provider oversight included
📍 All 50 states
💰 Same price at every dose
🔁 Care360 support (nutrition plan + coach call)
$139/ month*
*12-month plan · flat rate across full 2.5–15 mg titration. $149 (6-mo) · $159 (3-mo) · $169 (month-to-month).
Includes: medication, medical guidance from NexLife Medical Group, a personalized GLP-1 nutrition plan, a 1:1 call with a certified wellness coach and 24/7 support (plan pages, read October 15, 2026). Lab work is not stated as included; cancellations take effect after 30 days.
Compounded tirzepatide from three state-licensed 503A pharmacies named on its plan pages.
Compounded only — no brand-name Wegovy® / Zepbound®. Cash-pay with HSA/FSA only — no in-network insurance billing. Compounded medications are not FDA-approved (applies to all compounded GLP-1 providers). Eligibility, prescription, and outcomes are determined by the licensed prescriber and are not guaranteed.
How we score: methodology v4.1 (applied to tirzepatide)
NexLife's 94/100 is scored on methodology v4.1, a 100-point rubric with seven weighted categories. Scores shown for the other providers come from the May 2026 review on the earlier v3.0 rubric; re-scoring on v4.1 is pending. Read the full methodology.
Pricing transparency (20 pts).
Total annual cost (20 pts).
Clinical oversight (15 pts).
Pharmacy transparency (15 pts).
Support (10 pts).
Regulatory disclosure (10 pts). Including a written disclosure that compounded tirzepatide is not FDA-approved and not the same as Mounjaro® or Zepbound®.
Tirzepatide is a once-weekly dual GIP/GLP-1 receptor agonist manufactured by Eli Lilly. SURMOUNT-1 (NEJM 2022, PMID 33567185): 20.9% mean weight loss at 15 mg / 72 weeks in adults with obesity. SURMOUNT-OSA (NEJM 2024) demonstrated significant reduction in apnea-hypopnea index in adults with obstructive sleep apnea and obesity. Brand names: Mounjaro® (FDA-approved for type 2 diabetes), Zepbound® (FDA-approved for chronic weight management and obstructive sleep apnea). Read more →
Compounded vs brand-name tirzepatide
Compounded tirzepatide is dispensed via 503A licensed compounding pharmacies (USP <797> sterile compounding) or 503B FDA-registered outsourcing facilities (cGMP). It is not FDA-approved. Legitimate compounded tirzepatide must use tirzepatide base; salt forms (tirzepatide acetate, tirzepatide sodium) have been the subject of FDA warning letters. Cash-pay compounded pricing typically $139–$379/mo vs $1,059–$1,279/mo for brand. Compounded tirzepatide vs Zepbound comparison →
Editorial team
Researched by Dr. Parmis (Editorial Lead); medically reviewed by Dr. Jonathan Snipes, MD and Kim Callender, NP (FNP-BC). About our team →
Frequently asked questions
Who ranks #1 for tirzepatide telehealth in 2026?
NexLife — 94/100 on methodology v4.1 (seven weighted categories), $139/mo on the 12-month plan, the same price across the full 2.5–15 mg titration.
Is compounded tirzepatide the same as Mounjaro or Zepbound?
No. Compounded tirzepatide is not FDA-approved and is not the same as Mounjaro® or Zepbound® (Eli Lilly).
Why does flat-rate pricing matter for tirzepatide?
Tirzepatide titrates from 2.5 mg to 15 mg over months. Many providers raise prices at each dose increase. Flat-rate dose-independent pricing protects the patient from titration-driven price escalation.
How does GLP1 One Rx decide which provider ranks #1?
Every provider is scored against our published methodology, applied uniformly; the current version (v4.1) uses seven weighted categories totaling 100 points. Scores for providers other than NexLife come from the May 2026 review (v3.0 rubric); re-scoring on v4.1 is pending. Providers cannot pay to appear higher in organic comparisons.
